1 / 5

Skeletal Myoblast Cells

Skeletal myoblasts, derived from satellite cells in skeletal muscle, possess significant regenerative capabilities. These cells can differentiate into muscle fibers with appropriate stimuli and are known for their resistance to ischemia. Harvested via biopsy from the vastus lateralis, these myoblasts undergo a 3-week in vitro culture before application. Clinical trials like MAGIC evaluated autologous skeletal myoblast injections for ischemic cardiomyopathy post-CABG, revealing no significant improvement in left ventricular ejection fraction but notable LV size reductions. Adverse event rates were comparable to controls.

shad-roach
Download Presentation

Skeletal Myoblast Cells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Skeletal Myoblast Cells

  2. Skeletal myoblasts • Derived from satellite cells in skeletal muscle • With appropriate stimulus, satellite cells differentiate into muscle fibers • Highly resistant to ischemia • Do not contract spontaneously • Do not differentiate into cardiomyocytes

  3. Skeletal myoblasts 2-3 cm biopsy sample of thigh vastus lateralis (12-18 g) explanted under local anesthesia Human skeletal myoblasts after 3-wk in vitro culture period (magnification ×40) Courtesy of Arshed A. Quyyumi, MD.

  4. Skeletal myoblast transplantation in post-MI HF patients Before surgery After surgery Menasché P et al. Lancet. 2001;357:279-80.

  5. Autologous skeletal myoblast injection for ischemic cardiomyopathy trial (MAGIC) • Patients: • Moderate to severe LVSD referred for CABG • Cells: • Muscle Bx from thigh • Skeletal muscle myoblasts cultured • Delivery: • Direct injection into scar at surgery • Results: • Stopped early by DSMB due to low enrollment rate • Adverse event rate similar (25% cells vs 20% controls) • ICD Therapy in 15% • No improvement in LVEF by TTE (primary outcome)* • LVEF improved by SPECT • Highly significant dose-dependent LV size decrease Cleland JGF et al. Eur J Heart Failure 2007;9:92-97.

More Related